Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds

The human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 have been linked to life-threatening adverse drug reactions to the anticonvulsants carbamazepine and oxcarbazepine. Identification of these haplotypes via pharmacogenetic techniques facilitates implementation of precision medicine to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amanda Buchner, Xiuying Hu, Katherine J. Aitchison
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/d63ba4082d6243569252bd1ed48ba888
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d63ba4082d6243569252bd1ed48ba888
record_format dspace
spelling oai:doaj.org-article:d63ba4082d6243569252bd1ed48ba8882021-11-18T17:55:32ZValidation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds1663-981210.3389/fphar.2021.713178https://doaj.org/article/d63ba4082d6243569252bd1ed48ba8882021-07-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.713178/fullhttps://doaj.org/toc/1663-9812The human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 have been linked to life-threatening adverse drug reactions to the anticonvulsants carbamazepine and oxcarbazepine. Identification of these haplotypes via pharmacogenetic techniques facilitates implementation of precision medicine to prevent such reactions. Using reference samples from diverse ancestral origins, we investigated the test analytical validity (i.e., ability to detect whether or not the haplotypes were present or absent) of TaqMan assays for single nucleotide variants previously identified as potentially being able to “tag” these haplotypes. A TaqMan custom assay for rs10484555 and an inventoried assay for rs17179220 and were able to identify with 100% sensitivity and 100% specificity HLA-B*15:02 and HLA-A*31:01 respectively. A custom assay for rs144012689 that takes into account a neighboring single nucleotide variant with manual calling was also able to identify HLA-B*15:02 with 100% sensitivity and 100% specificity. A custom assay for rs106235 identified HLA-A*31:01 with 100% sensitivity and 95% specificity. The slight reduction in specificity for the latter was owing to another haplotype (HLA-A*33:03) also being detected. While any positive call using the rs106235 assay could therefore be further investigated, as the presence of the HLA-A*31:01 haplotype confers adverse drug reaction risk, the absence of false negatives (indexed by sensitivity) is more important than false positives. In summary, we present validated TaqMan assay methodology for efficient detection of HLA haplotypes HLA-B*15:02 and HLA-A*31:01. Our data are relevant for other genotyping technologies that identify, or have the potential to identify, these haplotypes using single nucleotide variants.Amanda BuchnerAmanda BuchnerXiuying HuKatherine J. AitchisonKatherine J. AitchisonKatherine J. AitchisonFrontiers Media S.A.articleHLA antigensadverse drug reactionscarbamazepinepsychiatrypharmacogeneticsprecision medicineTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution DOAJ
collection DOAJ
language EN
topic HLA antigens
adverse drug reactions
carbamazepine
psychiatry
pharmacogenetics
precision medicine
Therapeutics. Pharmacology
RM1-950
spellingShingle HLA antigens
adverse drug reactions
carbamazepine
psychiatry
pharmacogenetics
precision medicine
Therapeutics. Pharmacology
RM1-950
Amanda Buchner
Amanda Buchner
Xiuying Hu
Katherine J. Aitchison
Katherine J. Aitchison
Katherine J. Aitchison
Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
description The human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 have been linked to life-threatening adverse drug reactions to the anticonvulsants carbamazepine and oxcarbazepine. Identification of these haplotypes via pharmacogenetic techniques facilitates implementation of precision medicine to prevent such reactions. Using reference samples from diverse ancestral origins, we investigated the test analytical validity (i.e., ability to detect whether or not the haplotypes were present or absent) of TaqMan assays for single nucleotide variants previously identified as potentially being able to “tag” these haplotypes. A TaqMan custom assay for rs10484555 and an inventoried assay for rs17179220 and were able to identify with 100% sensitivity and 100% specificity HLA-B*15:02 and HLA-A*31:01 respectively. A custom assay for rs144012689 that takes into account a neighboring single nucleotide variant with manual calling was also able to identify HLA-B*15:02 with 100% sensitivity and 100% specificity. A custom assay for rs106235 identified HLA-A*31:01 with 100% sensitivity and 95% specificity. The slight reduction in specificity for the latter was owing to another haplotype (HLA-A*33:03) also being detected. While any positive call using the rs106235 assay could therefore be further investigated, as the presence of the HLA-A*31:01 haplotype confers adverse drug reaction risk, the absence of false negatives (indexed by sensitivity) is more important than false positives. In summary, we present validated TaqMan assay methodology for efficient detection of HLA haplotypes HLA-B*15:02 and HLA-A*31:01. Our data are relevant for other genotyping technologies that identify, or have the potential to identify, these haplotypes using single nucleotide variants.
format article
author Amanda Buchner
Amanda Buchner
Xiuying Hu
Katherine J. Aitchison
Katherine J. Aitchison
Katherine J. Aitchison
author_facet Amanda Buchner
Amanda Buchner
Xiuying Hu
Katherine J. Aitchison
Katherine J. Aitchison
Katherine J. Aitchison
author_sort Amanda Buchner
title Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
title_short Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
title_full Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
title_fullStr Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
title_full_unstemmed Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
title_sort validation of single nucleotide variant assays for human leukocyte antigen haplotypes hla-b*15:02 and hla-a*31:01 across diverse ancestral backgrounds
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/d63ba4082d6243569252bd1ed48ba888
work_keys_str_mv AT amandabuchner validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
AT amandabuchner validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
AT xiuyinghu validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
AT katherinejaitchison validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
AT katherinejaitchison validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
AT katherinejaitchison validationofsinglenucleotidevariantassaysforhumanleukocyteantigenhaplotypeshlab1502andhlaa3101acrossdiverseancestralbackgrounds
_version_ 1718420755918618624